Skip to content

Benjamin Bader

Benjamin Bader

Company: Bayer AG

Job title: Senior Scientist, Small Molecule Innovation


Benjamin Bader is a senior  biochemist and cell-biologist at Small Molecule Innovation Bayer AG. Engaged in Assay Development & HTS for Lead Discovery projects his research has been focused on pharma oncology projects in the areas of signal transduction (Ras-pathway), cell cycle (spindle checkpoint), immune-oncology, DNA-damage signalling and hormone-dependent tumours.  Prior to his career in large pharma starting at Schering AG in 2001, he worked for the German biotech Vasopharm. Benjamin graduated in 1996 in human biology at the University of Marburg, Germany, followed by a PhD at the Max-Planck-Institute for Molecular Physiology in Dortmund, Germany, where he studied lipid modification of Ras proteins together with Prof. Wittinghofer and Prof. Waldmann.


Disruption of the RAS-SOS1 Interaction – Enabling Lead Discovery by a Combination of High-Throughput and Fragment Screening 12:15 pm

Combination of high-throughput & fragment screening enabled a new approach to target KRAS Structure-guided optimization of potent and selective SOS1 inhibitors Cellular data support a possible combination potential of SOS1 inhibitors with covalent inhibitors of KRASG12CRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.